Mandate

Vinge has advised BAE Systems Bofors on the acquisition of Aston Harald Mekaniska Verkstad

BAE Systems is a world-leading defence group with a presence in Sweden through, among others, BAE Systems Bofors in Karlskoga, a supplier of weapon systems, artillery and ammunition. The acquisition is strategically motivated and aims to strengthen the Swedish defence industry's production capacity.

Aston Harald is a Kristinehamn-based supplier of precision-machined components for the defence and aerospace industries and has been an important supplier to BAE Systems. By integrating Aston Harald into the group, BAE Systems secures a critical part of its supply chain and increases its ability to meet the growing demand for defence systems such as ARCHER, TRIDON and the naval guns 40 Mk4 and 57 Mk3. Completion of the transaction is subject to customary conditions.

Vinge's team consisted primarily of Jonas Bergström, Peter Sundgren, Viktor Ramhult, Johanna Barfoed, Nora Karlsson (M&A), Johan Cederblad, Stina Larsson (Environment), Louisa Fagarasan (Employment), Eva Fredrikson, Siri Blomberg, Axel Lennartsson, Malin Dejke (IT/CC), Anders Leissner (International Trade and Compliance) and Gabriel Chabo (Banking & Finance). 

Read the client's press release here.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026